pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Apr 28·1 min read
save

Lilly strikes second partnership this year for recombinase-based gene editing

Decades before CRISPR gene editing was invented, scientists tried to manipulate genes with enzymes called recombinases. The proteins were precise but proved tricky to use because they were hardwired to target specific stretches of bacterial ...

Apr 28, 2026·read at Endpoints ↗

Ali Madani, Profluent CEO (Carlos Rodrigues/Sportsfile for Web Summit via Getty Images) April 28, 2026 07:00 AM EDT DealsCell/Gene Tx Lil­ly strikes sec­ond part­ner­ship this year for re­com­bi­nase-based gene edit­ing Ryan Cross Senior Science Correspondent Decades be­fore CRISPR gene edit­ing was in­vent­ed, sci­en­tists tried to ma­nip­u­late genes with en­zymes called re­com­bi­nas­es. The pro­teins were pre­cise but proved tricky to use … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

source

Reporting by Endpoints.

read at Endpoints ↗
95 words · retrieved Apr 29
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
LILLY
topics
CRISPR/Cas94

related stories

  • 5h agoNovartis may cut around 130 in Switzerland while relocating biologics productionBioSpace
  • Aug 5STAT+: Once again, child dies in gene-editing trial in China, rekindling debate on transparency and safetySTAT
  • Aug 5STAT+: Moderna launches early trial of Ebola mRNA vaccineSTAT
  • Aug 5STAT+: Exemption of rare disease therapies in drug-pricing pilots would wipe out huge savings, analysis findsSTAT
  • Aug 5STAT+: Senate inquiry suggests Trump administration softened kratom and tobacco policies in quid pro quoSTAT